Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

Colorectal cancer (CRC) is one of the most common cancers; ∼20% of patients have metastases at diagnosis, and 50%-60% subsequently develop metachronous metastases. Bone involvement, despite being rare, is usually associated with higher disease burden, worse prognosis, impaired quality of life, and s...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ESMO open 2022-12, Vol.7 (6), p.100606-100606, Article 100606
Hauptverfasser:	Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., Santini, D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bevacizumab - pharmacology Bevacizumab - therapeutic use bone metastases Bone Neoplasms - drug therapy Camptothecin - therapeutic use Colonic Neoplasms - drug therapy colorectal cancer Colorectal Neoplasms - pathology Fluorouracil - pharmacology Fluorouracil - therapeutic use Humans Original Research Prognosis Quality of Life triplet chemotherapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!